We observed that AFP levels were more predictive of HCC during ETV therapy at 12 months than at baseline; this is because the elevated AFP levels in patients commencing antiviral therapy were related to the hepatitis activity and were minimized through NA therapy. Here, AFP is linked to hepatitis A virus infection.